September 1, 2021 ImmunOs Therapeutics AG Appoints Seasoned Exec Jeffrey Abbey as Chief Operating Officer and High-Caliber Clinical and Scientific Advisors.
Read Article
April 12, 2021 ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases.
Read Article
November 13, 2020 ImmunOs Therapeutics AG Presents Data from their iosH2 Program at the Society for Immunotherapy of Cancer’s (SITC) 2020 Annual Meeting.
Read Article
December 10, 2019 ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials.
Read Article
September 18, 2018 UZH Life Sciences Fund and Schroder Adveq Invest in ImmunOs Therapeutics AG to Support Advancement of their Immunotherapy Platform for Cancer.
Read Article
December 8, 2017 ImmunOs Therapeutics AG closes 2.3 Million Financing to Support Lead Clinical Candidate Program Acceleration.
Read Article
October 30, 2017 ImmunOs Therapeutics AG appoints Pamela Carroll, Ph.D., a Leading Industry and Academic Oncology Drug Discovery Expert to the Scientific Advisory Board.
Read Article
October 25, 2017 ImmunOs Therapeutics AG Partners with Locust Walk to Support Business Development Activities for their Novel Innate Immunity Targeting Immunotherapy Platform for Cancer.
Read Article
August 7, 2017 ImmunOs Therapeutics AG appoints Leading U.S. Based Academic and Industry Oncology, Immunology, and Product Development Experts to the Scientific Advisory Board.
Read Article
June 6, 2017 ImmunOs Therapeutics AG appoints Sean R. Smith as new Chief Executive Officer and Dr. Osiris Marroquin-Belaunzaran as Chief Scientific Officer.
Read Article